ANDA Same-Day Filers Should Share Exclusivity, Industry Lawyer Says
Executive Summary
FDA should allow ANDA applicants who file the first Paragraph IV certifications against a patent on the same day to share 180-day exclusivity, industry attorney David Adams said at a Food & Drug Law Institute conference in Washington, D.C. April 2
You may also be interested in...
Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
FDA's determination that Purepac is eligible for 180-day generic exclusivity on gabapentin capsules (Pfizer's Neurontin) was reasonable and "an appropriate application of administrative discretion," D.C. federal court Judge Ellen Segal Huvelle ruled April 25
Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
FDA's determination that Purepac is eligible for 180-day generic exclusivity on gabapentin capsules (Pfizer's Neurontin) was reasonable and "an appropriate application of administrative discretion," D.C. federal court Judge Ellen Segal Huvelle ruled April 25
Citizen Petition Proposed Rule Withdrawn; FDA Cites Improved Response Rate
FDA is withdrawing its proposed rule to limit citizen petitions due to improvements in its response rate